Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia
- 11 December 2019
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 472, 132-141
- https://doi.org/10.1016/j.canlet.2019.11.040
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health-USA (1R15GM116043-01)
- St. John's University Research Seed Grant (579-1110-7002)
This publication has 47 references indexed in Scilit:
- Synergistic Apoptosis of CML Cells by Buthionine Sulfoximine and Hydroxychavicol Correlates with Activation of AIF and GSH-ROS-JNK-ERK-iNOS PathwayPLOS ONE, 2013
- Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignanciesCancer Chemotherapy and Pharmacology, 2013
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsNature, 2010
- Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2Cancer Research, 2008
- Development of the Predictor hERG Fluorescence Polarization Assay Using a Membrane Protein Enrichment ApproachASSAY and Drug Development Technologies, 2008
- Glutathione and apoptosisFree Radical Research, 2008
- PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancerMolecular Cancer Therapeutics, 2007
- Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitorsBlood, 2007
- Crystal Structure of the T315I Mutant of Abl KinaseChemical Biology & Drug Design, 2007
- Phenylamino‐Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)Archiv der Pharmazie, 1996